Royalty Pharma plc (RPRX) announced a research and development co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ4804 is a coantibody therapy that blocks the complementary interleukin23 and tumor necrosis factor pathways.
Royalty Pharma is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products and 19 development-stage product candidates.
In pre-market trading on NasdaqGS, Royalty Pharma shares are up 1.4 percent to $47.00.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.